Moawia Mohammed Ali Elhassan/LinkedIn
May 22, 2025, 16:47
Moawia Mohammed Ali Elhassan: The NEOPAN Trial Highlights FOLFIRINOX’s Benefits for Locally Advanced Pancreatic Cancer
Moawia Mohammed Ali Elhassan, Associate Professor at the University of Gezira, shared a post on LinkedIn:
“Advancing Treatment for Locally Advanced Pancreatic Cancer (LAPC): The NEOPAN Trial Highlights FOLFIRINOX’s Benefit
Building on its proven efficacy in metastatic and adjuvant settings, FOLFIRINOX was evaluated against gemcitabine in LAPC.
This trial, recently published in JCO, showed a significant improvement in PFS with FOLFIRINOX, which was also well-tolerated in LAPC. While OS didn’t differ significantly.
It’s important to note a study limitation: the complex definition of LAPC means these findings may not be universally generalizable across all LAPC presentations.”
Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet,Pierre Vanelslander, MD, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche
You can read the Full Article on Journal of Clinical Oncology.
More posts featuring Moawia Mohammed Ali Elhassan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 22, 2025, 16:22
May 22, 2025, 15:55
May 22, 2025, 14:59
May 22, 2025, 14:41